Pacira BioSciences Inc. (NASDAQ: PCRX) filed an investor presentation ahead of its June 9, 2026 annual stockholder meeting, urging shareholders to vote for its board nominees on blue proxy cards and reject competing candidates from DOMA Perpetual Capital Management LLC.

The company reported 2025 revenue of $726.4 million with GAAP gross margins of 79.4%. EXPAREL volume growth accelerated to 8% in the second half of 2025. First quarter 2026 results showed EXPAREL revenue of $143.3 million, up 5% year-over-year, ZILRETTA revenue of $26.8 million, up 15%, and iovera revenue of $6.2 million, up 21%.

Pacira has returned $200 million to stockholders under a $300 million share repurchase program authorized in April 2025. The company reached a settlement in EXPAREL patent litigation securing exclusivity through 2030.

The board has added five new independent directors since October 2023 and nominated a sixth for election. If elected, the board would be 89% independent with average tenure of approximately 4.6 years.

Pacira criticized DOMA's nominees as lacking industry experience and public company governance expertise. The company said DOMA's plan includes cost cuts, discontinuing pipeline development, replacing CEO Frank D. Lee, and pursuing an immediate sale process.

Stockholders of record as of April 22, 2026 are entitled to vote at the annual meeting. The company advised shareholders to disregard white proxy cards from DOMA and vote using blue proxy cards.